MXCT (MaxCyte) Buyback Yield % : 0.00 (As of Apr. 22, 2025)

View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

MaxCyte's current buyback yield was 0.00%.

MaxCyte Buyback Yield % Historical Data

The historical data trend for MaxCyte's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Buyback Yield % Chart

MaxCyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-8.12

-22.89

-0.06

MaxCyte Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-0.06	-	-	-	-

Competitive Comparison of MaxCyte's Buyback Yield %

For the Medical Devices subindustry, MaxCyte's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MaxCyte's Buyback Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where MaxCyte's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

MaxCyte Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

MaxCyte's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	439.75776
	=	0.00%

MaxCyte's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	0)		/	439.75776
	=	0.00%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

MaxCyte Buyback Yield % Related Terms

Thank you for viewing the detailed overview of MaxCyte's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

MXCT:UK MYE0:Germany

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Executives

Douglas J Swirsky	officer: Chief Financial Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
John Joseph Johnston	director	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Stanley C Erck	director	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Thomas M. Ross	officer: EVP, Global Sales	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud	officer: EVP and General Counsel	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler	director, officer: President and CEO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen	officer: Chief Scientific Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy	officer: Chief Financial Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz	officer: SVP and CAO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell	director	C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke	director	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203